Dr. Leslie receives honoraria or speaker's fees from Merck Frosst Canada, Sanofi-Aventis, and Genzyme Canada Ltd., research support from Merck Frosst Canada, and unrestricted educational grants from Procter & Gamble Pharmaceuticals, Novartis Pharmaceuticals Canada, and Amgen, Canada. Dr. Hans receives honoraria from Perceptive Informatics and Cardea Technology and research support from Hologic, Med-imaps, GE Healthcare, and DAL Foundation. He has stock options or a patent relationship with Synarc, Ascendys, and Med-Imaps.
Commentary
You have full text access to this OnlineOpen article
On Lumpers and Splitters: The FRAX Debate Continues
Article first published online: 28 SEP 2009
DOI: 10.1359/jbmr.090902
Copyright © 2009 ASBMR
Additional Information
How to Cite
Leslie, W. D. and Hans, D. (2009), On Lumpers and Splitters: The FRAX Debate Continues. J Bone Miner Res, 24: 1789–1792. doi: 10.1359/jbmr.090902
Publication History
- Issue published online: 4 DEC 2009
- Article first published online: 28 SEP 2009
REFERENCES
- 1, , , , , 2009 FRAX and its applications to clinical practice. Bone 44 : 734–743.
- 2, , , , , 2001 The burden of osteoporotic fractures: A method for setting intervention thresholds. Osteoporos Int 12 : 417–427.
- 3, , , , , , , , , 2005 Assessment of fracture risk. Osteoporos Int 16 : 581–589.
- 4, , , , 2008 FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19 : 385–397.
- 5, , , , , , , , , , , , , , , , , , , , , , , , , , , , 2007 The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 : 1033–1046.
- 6, , , 2009 Prognosis and prognostic research: Application and impact of prognostic models in clinical practice. BMJ 338 : 1487–1490.
- 7, , , 2009 Prognosis and prognostic research: Validating a prognostic model. BMJ 338 : 1432–1435.
- 8, , , 2009 Prognosis and prognostic research: Developing a prognostic model. BMJ 338 : 1373–1377.
- 9, , , , 2009 Prognosis and prognostic research: What, why, and how ? BMJ 338 : 1317–1320.
- 102008 Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Springer, New York, NY, USA.
- 11, , , , , 2009 FRAX and risk of vertebral fractures: The Fracture Intervention Trial (FIT). J Bone Miner Res 24 : 000–000.Direct Link:
- 12, , , , , , , , , , 2009 Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24 : 495–502.Direct Link:
- 13, , , , , , , 2000 Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11 : 669–674.
- 14, , , , , , , , , 2004 Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: Results from the Women's Health Initiative observational study and clinical trials. Menopause 11 : 264–274.
- 15, , , , , , , , , , , , , , , , 2004 A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 : 375–382.
- 16, , , 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114 : 919–923.
- 17, 2009 An independent external validation and evaluation of QRISK cardiovascular risk prediction: A prospective open cohort study. BMJ 339 : b2584.
- 18, , , , 2009 QRISK or Framingham for predicting cardiovascular risk ? BMJ 339 : b2673.
- 19, , , , , , , , , , , , , , , , , 2008 Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148 : 197–213.
- 20, , , , , , , 2008 Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155.
- 21, , , , , , , 2008 Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523.
- 22, , 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 : 1254–1259.
- 231969 On lumpers and splitters, or the nosology of genetic disease. Perspect Biol Med 12 : 298–312.

1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
